Search Results
Jul 02, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jul 02, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jul 02, 2025, 09:07 ET X-Therma Showcases Groundbreaking Organ Preservation Technology at Johns Hopkins' "Hopkins on the Hill" Event
XT-ViVo®, and TimeSeal®, are designed to extend the reach of regenerative medicines e.g. cell and gene therapies, tissue engineering and organ transplants, enabling ultra-long preservation and global organ sharing. With an expanding presence in
More news about: X-Therma Inc.
Jul 02, 2025, 08:46 ET Spartanburg Regional Healthcare System (SRHS) Selects AccessDx Laboratory as Pharmacogenomics (PGx) Program Partner
its commitment to helping deliver discrete drug-gene insights at providers' fingertips and supporting effective utility with educational resources and publications." SRHS will leverage AccessDx Laboratory's experts and their wealth of drug-gene knowledge and research findings to educate clinical
More news about: AccessDx Laboratory
Jul 02, 2025, 08:32 ET Pusan National University Researchers Develop Tool to Improve CRISPR Off-Target Predictions Using Genetic Variants
BUSAN, South Korea, July 2, 2025 /PRNewswire/ -- CRISPR-based gene editing holds great promise, but off-target effects remain a major concern, especially across diverse genetic backgrounds. A new study presents a web-based
More news about: Pusan National University
Jul 02, 2025, 08:31 ET O'Shaughnessy Ventures Awards Fellowship to Researcher Tackling the Biology of Aging
Bioengineer Benjamin Arya awarded $100K to build next-generation gene-editing tools and delivery systems GREENWICH, Conn., July
More news about: O'Shaughnessy Ventures
Jul 02, 2025, 02:09 ET CCTV+: Global Audience Captivated by Fierce "Milu Deer King" Rivalries in China's Wetland
Through captive breeding, disease prevention, and wetland restoration, Dafeng Milu National Nature Reserve has become the world's largest milu deer gene bank. Its wild population now reaches 3,673 deer — over 90% of the entire global total — marking a major conservation success for the Yancheng's wetlands.
More news about: CCTV+
Jul 01, 2025, 17:46 ET NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight
innovation and regulatory support for rare diseases. Advances in gene therapy, mRNA technologies, and protein replacement strategies are enabling more precise and durable correction of NOX-related deficiencies. For instance, gene therapy approaches aimed at correcting NOX2 mutations in hematopoietic
More news about: DelveInsight Business Research, LLP
Jul 01, 2025, 17:31 ET Frontotemporal Dementia Market Sees Rise in Precision Medicine and Gene Therapy Approaches | DelveInsight
enrolling both symptomatic and at-risk individuals with FTD-GRN. Passage Bio is developing PBFT02, a gene therapy that employs an AAV1 vector to deliver a modified GRN gene to patient cells. The therapy is under investigation in Phase I/II trials for FTD with GRN mutations, supported by
More news about: DelveInsight Business Research, LLP
Jul 01, 2025, 16:21 ET SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Class Period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy ("Duchenne"), including ELEVIDYS (a prescription gene therapy intended for a limited category of people with Duchenne). The Sarepta Therapeutics class action lawsuit alleges that
More news about: Robbins Geller Rudman & Dowd LLP
Jul 01, 2025, 16:19 ET iconPCR™: Powering the Next Wave of Metagenomics and Microbiome Discovery
delivering superior microbial profiling results. SeqCenter's full-length 16S service provides high-accuracy reads spanning the entire 1,500bp 16S gene (V1-V9 regions), offering significantly enhanced taxonomic resolution compared to traditional short-read methods that focus on only one or two hypervariable
More news about: n6
Jul 01, 2025, 11:23 ET Global Market for Media, Sera, and Reagents in Biotechnology to Reach $9.3 Billion by 2029
worldwide. Rising investments in biopharmaceuticals: Growing investments in biopharmaceuticals are fueling innovation in drug development, gene therapy, and personalized medicine. This surge in funding is driving advances in biotechnology, improving treatment options for various diseases.
More news about: BCC Research LLC
Jul 01, 2025, 10:30 ET Residual DNA Testing to Hit $370M by 2030 -- The Silent Guardian of Biologics Safety | MarketsandMarkets™
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89689614 Why is residual DNA testing a non-negotiable in biomanufacturing? The shift from small molecules to monoclonal antibodies, gene therapies, and vaccines has made biologics the backbone of modern medicine. With that evolution comes a heightened risk of contamination and compliance
More news about: MarketsandMarkets
Jul 01, 2025, 10:05 ET Rycor LLC expands into commercial heating and cooling market with new leadership
including multi-family housing developments, office buildings and other commercial properties. Rycor has appointed Gene Cattani to the newly created role of Director of Business Development to lead the growth of commercial markets. Cattani is a 20-year veteran
More news about: Rycor Heating & Cooling
Jul 01, 2025, 10:00 ET Rise of High-Cost Insurance Claims Elevate Need to Mitigate Financial Risks, according to QBE North America's Accident & Health Market Report
and pre-term birthsGrowing impact of specialty pharmaceuticals and continued strain on patient affordabilityRecord-breaking cell and gene therapy approvals, with advanced treatment options for autoimmune diseases and rare genetic conditionsSocietal factors that could be driving
More news about: QBE North America
Jul 01, 2025, 09:00 ET Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland
Allan Sheffield, Director of Gene by Gene and myDNA, said: "For myDNA, the PHOENIX Study embodies the future of healthcare. Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to
More news about: Gene by Gene
Jul 01, 2025, 08:31 ET Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
New Zealand]. The FDA granted Breakthrough Therapy designation for zanidatamab development in patients with previously treated HER2 gene-amplified BTC, and two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care
More news about: Jazz Pharmaceuticals plc
Jun 30, 2025, 17:30 ET Ecovyst Issues 2024 Sustainability Report
https://www.ecovyst.com. For more information:Gene Shiels – Director of Investor Relations(484) 617 [email protected]
More news about: Ecovyst Inc.
Jun 30, 2025, 14:25 ET Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®
is fueled by rising demand for biologicals and biosimilars, increasing costs of traditional drug development, growing demand for cell therapies and gene therapies, and strategic consolidation among Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs).
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 12:43 ET From Agilent to ZEISS: SDi's 2025 Report Dissects Market Share and Growth Across 21 Lab Instrument Leaders
Alice Kan, Market Analytics Manager at SDi. "As a result, vendors increasing share are those leaning into growth areas like oncology, cell and gene therapy, sustainable materials, and AI-enabled lab automation—while others face stagnation or retreat." Key insights from the report include:
More news about: Strategic Directions International
Jun 30, 2025, 12:29 ET Regenerative Medicine Market to Reach $45.66 Billion by 2032, Growing at a CAGR of 22.0% from 2025, Says Meticulous Research®
According to a comprehensive market research report titled "Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User - Global
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:30 ET Metagenomics Market to Reach $7.78 Billion by 2032, Growing at a CAGR of 15.8% from 2025, Says Meticulous Research®
laboratories, diagnostic centers, and field research applications. The increasing applications in human microbiome mapping, drug discovery, and microbial gene profiling are driving sustained growth in consumables demand. The growing adoption of metagenomic kits in diagnostic settings is exemplified
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:00 ET Whole Genome Sequencing Market to Reach $8.35 Billion by 2032, Growing at a CAGR of 15.4% from 2025, Says Meticulous Research®
Research Applications segment dominates the market, driven by increasing use of whole genome sequencing to identify novel drug targets, rising demand for gene-based medicines, growing investments in drug research and development, and expansion of research programs focused on personalized medicine. Get
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:30 ET Neurogenomics Market to Reach $5.48 Billion by 2032, Growing at a CAGR of 17% from 2025, Says Meticulous Research®
precision medicine. Additional drivers include increased pharmaceutical R&D expenditures, improvements in regulatory and reimbursement frameworks for gene sequencing, rising healthcare expenditures, and increased funding for research activities. There is also a growing emphasis on early detection and prevention
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:06 ET AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
AvenCell's unique and proprietary allogeneic technology is differentiated from numerous previous cell engineering approaches by applying multiple gene editing steps that ensure a patient's immune system (both innate and adaptive components) is left with no ability to reject the donor cells. Importantly,
More news about: AvenCell Therapeutics, Inc.